drugset

drugset / Trial / NCT02524379

Spinal Cord Injury Neuroprotection With Glyburide

NCT02524379 ↗

Phase 1/2 Terminated 3 enrolled Ohio State University

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety of using oral Glyburide in patients with acute traumatic cervical spinal cord injuries (SCI).

Timeline

Start: 2017-02-14
Primary completion: 2021-02-08
Completion: 2021-02-08

Publications

Minnema AJ, Mehta A, Boling WW, Schwab J, Simard JM, Farhadi HF. SCING-Spinal Cord Injury Neuroprotection with Glyburide: a pilot, open-label, multicentre, prospective evaluation of oral glyburide in patients with acute traumatic spinal cord injury in the USA. BMJ Open. 2019 Oct 10;9(10):e031329. doi: 10.1136/bmjopen-2019-031329.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Glyburide	Small molecule	2.5 mg	Oral

Indications